

CIN: L40100TN1992PLC129301

Date: 14.11.2021

To,
The Department of Corporate Services,
Bombay Stock Exchange Limited,
Floor 25, P J Tower, Dalal Street,
Mumbai - 400001.

(Scrip code: 526445)


Dear Sir/Madam,

Sub: Covering Letter

Please find attached Board Outcome for the meeting of Board of directors of the Company held on 14th November, 2021.

Kindly take the same on your records.

Yours faithfully,



Kasiraman Sayee Sundar
Managing Director
DIN: 01295584

CIN: L40100TN1992PLC129301
November 14, 2021

To,
The Department of Corporate Services,
Bombay Stock Exchange Limited,
Floor 25, P J Tower, Dalal Street,
Mumbai - 400001.

(Scrip code: 526445)

Dear Sir/Madam,

Sub: Outcome of the Board meeting

This is to inform you that pursuant to Regulation 30 and Regulation 33 of SEBI LODR, Regulations 2015, the meeting of Board of Directors of the company held on 14th November, 2021 i.e. today inter alia considered and approved the following agenda:

1. The Unaudited Standalone and Consolidated Financial Results with the Limited Review Report of the statutory auditors of the company for the quarter and half year ended 30th September, 2021(Q2).
2. Resignation of Mrs. Roopa Ravikumar, Company Secretary & Compliance officer with effect from 30th October 2021.
3. Appointment of Ms. R. Charu Latha as the Company Secretary & Compliance officer with effect from 8th November, 2021.
4. Filing of an application before the Hon'ble NCLT, Chennai for reopening of Books of Accounts of the Company in order to implement the approved Scheme of Amalgamation passed by the Hon'ble NCLT, Chennai dated 5th August, 2021. Pursuant to the order, the merged financials for the FYs 2018-19, 2019-20 & June quarter, 2020 has been submitted to the exchange and the same has been reflected in the BSE records of the Company.

However, the merged financials has not been updated with the ROC. The same shall be done only by way of anm order of NCLT. Hence, an application has to be filed to bring in light the combined financials in all the public records.

5. The Board amongst discussion of other items, also considered the proposal of incorporation of a subsidiary company in the name "IBL INVESTMENTS LTD" or "INDRAYANI INVESTMENTS LIMITED", or such other name as may be approved by the Registrar of Companies. The Board has appointed and authorized the members and first directors of the Company. Subsequently, necessary authorizations were approved to perform further actions related to ROC.
6. The Board has not taken up the business of appointment of Secretarial Auditor during the hours of the meeting and decided to consider it in any other upcoming meeting.

The meeting commenced at 12.00pm and concluded at 1.30pm. Kindly take the same on your records.

Thanking you

Yours Sincerely,



Kasiraman Sayee Sundar
Managing Director
DIN: 01295584

INDRAYANI BIOTECH LIMITED

Regd. Office :

Block 1 Module No.33, 3rd Floor, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY CHENNAI - 600032

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2021

Rs. In Lakhs

	PARTICULARS	Quarter Ended			Half Year Ended		Year Ended
Sr No	PARTICULARS	30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20	30-Mar-21
A	Date of start of reporting period	01-07-2021	01-04-2021	01-07-2020	01-04-2021	01-04-2020	01-04-2020
B	Date of end of reporting period	30-09-2021	30-06-2021	30-09-2020	30-09-2021	30-09-2020	31-03-2021
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	(a) Net Sales/Revenue from Operations	1,430.99	1,424.41	470.73	2,855.40	811.84	2,100.73
	(b) Other Income	3.70	2.53	3.33	6.23	10.42	26.34
	Total Income from Operations	1,434.69	1,426.94	474.06	2,861.63	822.26	2,127.07
2	Expenses						
	(a) Cost of Materials consumed	954.64	940.59	215.04	1,895.24	788.30	1,575.90
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade						
	(c) Employee benefits expenses	254.79	279.22	117.57	534.02	356.65	571.19
	(d) Finance Costs	52.90	32.24	31.15	85.14	60.42	196.14
	(e) Depreciation and amortisation expense	8.46	8.41	21.25	16.87	42.49	40.25
	(f) Other expenses	53.80	87.10	77.33	140.91	196.68	421.28
	Total Expenses	1,324.59	1,347.56	462.33	2,672.17	1,444.52	2,804.76
3	Total profit / (Loss) before exceptional items and tax	110.09	79.37	11.72	189.46	(622.27)	(677.70)
4	Exceptional Items						(410.98)
5	Total profit / (Loss) before tax	110.09	79.37	11.72	189.46	(622.27)	(1,088.67)
7	Tax Expenses						
	Current Tax						
	Deferred Tax						
	Total Tax Expenses						
8	Net Profit Loss for the period from continuing operations	110.09	79.37	11.72	189.46	(622.27)	(1,088.67)
9	Profit (loss) from discontinued operations before tax						
10	Tax expense of discontinued operations						
11	Net profit (loss) from discontinued operation after tax						
12	Share of profit (loss) of associates and joint ventures accounted for using equity method						
13	Total profit (loss) for period	110.09	79.37	11.72	189.46	(622.27)	(1,088.67)
14	Other comprehensive income net of taxes						
15	Total Comprehensive Income for the period						
16	Total profit or loss, attributable to						
	Profit or loss, attributable to owners of parent	110.09	79.37	11.72	189.46	(622.27)	(1,088.67)
	Total profit or loss, attributable to non-controlling interests						
17	Total Comprehensive income for the period attributable to						
	Comprehensive income for the period attributable to owners of parent						
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests						
18	Details of equity share capital						
	Paid-up equity share capital	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00

K. durga Lakshmi

MANAGING DIRECTOR
DIN: 01295584

19	Details of debt securities						
	Paid-up debt capital						
	Face value of debt securities						
20	Reserves excluding revaluation reserve						
21	Debenture redemption reserve						
22	Earnings per share						
i	Earnings per equity share for continuing operations	0.32	0.23	0.03	0.55	(1.82)	(3.18)
	Basic earnings (loss) per share from continuing operations	0.32	0.23	0.03	0.55	(1.82)	(3.18)
	Diluted earnings (loss) per share from continuing operations						
ii	Earnings per equity share for discontinued operations						
	Basic earnings (loss) per share from discontinued operations						
	Diluted earnings (loss) per share from discontinued operations						
iii	Earnings per equity share						
	Basic earnings (loss) per share from continuing and discontinued operations	0.32	0.23	0.03	0.55	(1.82)	(3.18)
	Diluted earnings (loss) per share from continuing and discontinued operations	0.32	0.23	0.03	0.55	(1.82)	(3.18)

K. Durga Shankar

MANAGING DIRECTOR
DIN: 01295584



M/s. INDRAYANI BIOTECH LIMITED		
CIN : L40100TN1992PLC129301		
BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032		
Unaudited Standalone Statement of Assets and Liabilities		Amount In Rs.
Particulars	As at 30-09-2021	As at 31-03-2021
ASSETS		
A) Non - Current Assets		
a) Property Plant and Equipment	11,14,57,770	11,27,51,448
b) Capital Work in Progress	13,71,95,717	13,71,95,717
c) Goodwill	3,83,52,734	3,83,52,734
d) Other Intangible assets		
e) Financial Assets		
--- (i) Investments	18,53,099	18,53,099
--- (ii) Other Financial Assets		
f) Other Non Current assets	1,14,10,621	1,32,66,121
B) Current Assets		
a) Inventories	95,08,281	1,08,38,060
b) Financial Assets		
--- (i) Investments		
--- (ii) Trade Receivables	9,55,68,968	4,76,80,467
--- (iii) Cash and cash Equivalents	27,19,868	62,64,738
--- (iii) Other Financial Assets	47,86,033	47,09,596
c) Other Current assets	2,71,22,348	2,55,70,546
Total Assets	43,99,75,439	39,84,82,526
EQUITY & LIABILITIES		
A) Equity		
a) Equity Share Capital	34,22,71,920	34,22,71,920
b) Other Equity	(12,38,24,082)	(14,27,70,005)
B) LIABILITIES		
Non - Current Liabilities		
a) Financial Liabilities		
--- (i) Borrowings	8,22,03,673	8,15,39,017
--- (ii) Other financial Liabilities		
b) Deferred Tax Liabilities	1,37,999	1,37,999
c) Other Non Current Liabilities		
Current Liabilities		
a) Financial Liabilities		
--- (i) Short Term Borrowings	8,16,27,541	7,27,85,753
--- (ii) Trade Payables		
----- (A) total outstanding dues of micro enterprises and small enterprises;		
----- (B) total outstanding dues of creditors other than micro enterprises and small enterprises	5,00,15,633	3,42,10,892
--- (iii) Other financial Liabilities		
b) Other Current Liabilities	2,88,873	18,12,247
c) Provisions	72,53,882	84,94,703
Total Equity & Liabilities	43,99,75,439	39,84,82,526

K. durga Shankar

MANAGING DIRECTOR
DIN: 01295584



M/s. INDRAYANI BIOTECH LIMITED
BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE,
GUINDY, CHENNAI, 600032

CIN : L40100TN1992PLC129301

Unaudited Standalone Statement of Cash Flow		Amount in Rs.	
Particulars	As on 30-Sep-21	As on 31-Mar-21	
Cash Flows From Operating Activities:-			
Net Profit after Taxation	1,89,45,923	(10,88,67,482)	
Adjustment for Non cash items			
Add : Impairment of Fixed Assets		2,09,74,141	
Add : Depreciation	16,86,520	40,25,167	
Less : Interest Income Notional (As per Ind AS 109)	(99,759)	(2,15,661)	
Add : Notional Rent as per IND AS	1,13,323	2,53,168	
Adjustment for Non Operating activities			
Add : Interest Paid	85,14,383	1,96,14,227	
Less : Interest income		-	
Cash Flow Before Working Capital changes:-	2,91,60,390	(6,42,16,439)	
Decrease (Increase) in Inventories	13,29,779	3,98,84,116	
Decrease (Increase) in Trade receivables	(4,78,88,501)	2,27,64,785	
Decrease (Increase) in other current assets	(17,41,561)	2,62,31,129	
(Decrease) Increase in Short term borrowings	88,41,788	48,14,896	
(Decrease) Increase in Trade payables	1,58,04,741	(2,83,55,873)	
(Decrease) Increase in Other Current liabilities	(15,23,374)	(30,78,280)	
(Decrease) Increase in Provisions	(12,40,821)	71,31,480	
Cash Flow Before Tax and Extraordinary Items:-			
Income Taxes Paid	-	-	
Net Cash Flow From Operating Activities	27,42,440	51,75,814	
Cash Flow from Investing Activities:-			
Less : Purchase of Capital Assets	(3,92,842)	(38,28,971)	
Less : Purchase of Investments	-	(17,19,099)	
Add : Rental Receipts		-	
Add : Amount of Interest Received		-	
Less : Sale of Capital Assets		1,20,000	
Decrease (Increase) in Loans and advances & Other assets	18,55,499	(2,00,124)	
Net Cash flow used in Investing Activities	14,62,657	(56,28,194)	
Cash Flow from Financing Activities:-			
Increase in Borrowings			
Interest Income Notional (As per Ind AS 109)	99,759	2,15,661	
Increase in Share capital		-	
Increase in Other Non current liabilities		-	
Interest expense	(85,14,383)	(1,96,14,227)	
Decrease in borrowings	6,64,656	1,20,94,882	
Net Cash Flow From Financing Activities	(77,49,968)	(73,03,684)	
Net Increase/(Decrease) in Cash and Cash Equivalents:-			
(Opening Balance)	62,64,739	1,40,20,803	
Net Cash Flow during the year	(35,44,871)	(77,56,065)	
(Closing Balance)	27,19,868	62,64,739	

K. durga

MANAGING DIRECTOR
DIN: 01295584



Notes:

1. The Unaudited Standalone and Consolidated financial results along with the Limited Review Report of the Statutory Auditors for the quarter and half year ended 30th September, 2021 are being forwarded to the Bombay stock exchange and is also available in the website of the Company (www.indrayani.com)
2. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors in the meeting held on 14th November, 2021.
3. The Company operates in single business segment. Hence no segment wise reporting figures are published.
4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter
5. Previous period figures have been regrouped wherever necessary.



Place: Chennai

Date: 14.11.2021

K SAYEE SUNDAR

MANAGING DIRECTOR

DIN: 01295584



Limited Review Report on Quarterly Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**Review Report to the Board of Directors,
Indrayani Biotech Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter ended September 2021. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Venkatesh & Co
Chartered Accountants
FRN: 004636S


CA Dasaraty V
Partner
M No: 026336
Place: Chennai
Date: 14th November 2021.
UDIN: 21026336AAAAJG6440



INDRAYANI BIOTECH LIMITED

Regd. Office :

Block 1 Module No.33, 3rd Floor,SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE,GUINDY CHENNAI - 600032

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2021

Rs. In Lakhs

	PARTICULARS	Quarter Ended			Half Year Ended		Year Ended
Sr N o	PARTICULARS	30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20	30-Mar-21
A	Date of start of reporting period	01-07-2021	01-04-2021	01-07-2020	01-04-2021	01-04-2020	01-04-2020
B	Date of end of reporting period	30-09-2021	30-06-2021	30-09-2020	30-09-2021	30-09-2020	31-03-2021
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	(a) Net Sales/Revenue from Operations	1,485.24	1,431.22	470.73	2,916.46	811.84	2,108.84
	(b) Other Income	3.70	2.56	3.33	6.26	10.42	26.50
	Total Income from Operations	1,488.95	1,433.78	474.06	2,922.73	822.26	2,135.34
2	Expenses						
	(a) Cost of Materials consumed	969.90	940.68	215.04	1,910.58	788.30	1,577.15
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade						
	(c) Employee benefits expenses	279.24	294.71	117.57	573.95	356.65	594.40
	(d) Finance Costs	52.90	32.24	31.15	85.14	60.42	196.14
	(e) Depreciation and amortisation expense	10.72	10.66	21.25	21.38	42.49	45.82
	(f) Other expenses	72.02	92.19	77.33	164.21	196.68	432.55
	Total Expenses	1,384.79	1,370.47	462.34	2,755.26	1,444.53	2,846.08
	Total profit / (Loss) before exceptional items and tax	104.15	63.31	11.72	167.46	(622.27)	(710.74)
3	Exceptional Items						(410.98)
4	Add:Share of Profit In Associates	(0.14)	1.21		1.06		0.28
5	Total profit / (Loss) before tax	104.01	64.51	11.72	168.53	(622.27)	(1,121.44)
7	Tax Expenses						
	Current Tax						
	Deferred Tax						
	Total Tax Expenses						
	Net Profit Loss for the period from continuing operations	104.01	64.51	11.72	168.53	(622.27)	(1,121.44)
8	Profit (loss) from discontinued operations before tax						
9	Tax expense of discontinued operations						
10	Net profit (loss) from discontinued operation after tax						
11							
12	Share of profit (loss) of associates and joint ventures accounted for using equity method						
13	Total profit (loss) for period	104.01	64.51	11.72	168.53	(622.27)	(1,121.44)
14	Other comprehensive income net of taxes						
15	Total Comprehensive Income for the period						
16	Total profit or loss, attributable to						
	Profit or loss, attributable to owners of parent	104.01	64.51	11.72	168.53	(622.27)	(1,121.44)

K. durga shankar

MANAGING DIRECTOR
DIN: 01295584



	Total profit or loss, attributable to non-controlling interests						
17	Total Comprehensive income for the period attributable to						
	Comprehensive income for the period attributable to owners of parent	106.42	67.25	11.72	173.66	(622.27)	(1,112.15)
	Total comprehensive income for the period attributable to owners of parent non controlling interests	(2.41)	(2.73)		(5.13)		(9.29)
18	Details of equity share capital						
	Paid-up equity share capital	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72	3,422.72
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
19	Details of debt securities						
	Paid-up debt capital						
	Face value of debt securities						
20	Reserves excluding revaluation reserve						
21	Debenture redemption reserve						
22	Earnings per share						
i	Earnings per equity share for continuing operations	0.30	0.20	0.03	0.49	(1.82)	(5.52)
	Basic earnings (loss) per share from continuing operations	0.30	0.20	0.03	0.49	(1.82)	(5.52)
	Diluted earnings (loss) per share from continuing operations						
ii	Earnings per equity share for discontinued operations						
	Basic earnings (loss) per share from discontinued operations						
	Diluted earnings (loss) per share from discontinued operations						
iii	Earnings per equity share						
	Basic earnings (loss) per share from continuing and discontinued operations	0.30	0.20	0.03	0.49	(1.82)	(5.52)
	Diluted earnings (loss) per share from continuing and discontinued operations	0.30	0.20	0.03	0.49	(1.82)	(5.52)

K. dnyu



MANAGING DIRECTOR
DIN: 01295584

M/s. INDRAYANI BIOTECH LIMITED CIN : L40100TN1992PLC129301 BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE, GUINDY, CHENNAI, 600032		
<i>Unaudited Consolidated Statement of Assets and Liabilities</i>		<i>Amount in Rs.</i>
<i>Particulars</i>	<i>As at 30-09-2021</i>	<i>As at 31-03-2021</i>
ASSETS		
A) Non - Current Assets		
a) Property Plant and Equipment	12,48,35,939	11,53,21,243
b) Capital Work in Progress	13,71,95,717	13,71,95,717
c) Goodwill	3,84,14,195	3,84,14,195
d) Other Intangible assets		
e) Financial Assets		
--- (i) Investments	2,25,800	1,19,373
--- (ii) Other Financial Assets		
f) Other Non Current assets	1,14,10,621	1,32,66,121
B) Current Assets		
a) Inventories	97,58,529	1,09,02,092
b) Financial Assets		
--- (i) Investments		
--- (ii) Trade Receivables	9,75,56,051	4,76,80,467
--- (iii) Cash and cash Equivalents	34,47,936	67,87,172
--- (iii) Other Financial Assets	47,86,033	47,09,596
c) Other Current assets	2,68,42,386	2,61,53,249
Total Assets	45,44,73,207	40,05,49,225
EQUITY & LIABILITIES		
A) Equity		
a) Equity Share Capital	34,22,71,920	34,22,71,920
b) Other Equity	-12,77,04,232	-14,50,70,310
b) Non Controlling Interest within Equity	30,88,929	36,02,296
B) LIABILITIES		
Non - Current Liabilities		
a) Financial Liabilities		
--- (i) Borrowings	9,34,13,220	8,15,39,017
--- (ii) Other financial Liabilities	-	-
b) Deffered Tax Liabilities	1,37,999	1,37,999
c) Other Non Current Liabilities	-	-
Current Liabilities		
a) Financial Liabilities		
--- (i) Short Term Borrowings	8,39,71,529	7,38,24,703
--- (ii) Trade Payables		
----- (A) total outstanding dues of micro enterprises and small enterprises;		
----- (B) total outstanding dues of creditors other than micro enterprises and small enterprises	5,01,86,073	3,33,58,219
--- (iii) Other financial Liabilities		
b) Other Current Liabilities	3,06,468	18,12,247
c) Provisions	88,01,301	90,73,134
Total Equity & Liabilities	45,44,73,207	40,05,49,225

K. durga Ind

MANAGING DIRECTOR
DIN: 01295584



M/s. INDRAYANI BIOTECH LIMITED
BLOCK I, MODULE NO.33, 3rd FLOOR, SIDCO ELECTRONIC COMPLEX, THIRU VI KA INDUSTRIAL ESTATE,
GUINDY, CHENNAI, 600032
CIN : L40100TN1992PLC129301

Unaudited Consolidated Statement of Cash Flow		Amount in Rs.	
Particulars	As at 30-09-2021	As at 31-03-2021	
Cash Flows From Operating Activities:-			
Net Profit after Taxation	1,68,52,711	-11,21,44,127	
Adjustment for Non cash items			
Add : Impairment of Fixed Assets		2,09,74,141	
Add : Depreciation	21,38,126	45,82,254	
Less : Interest Income Notional (As per Ind AS 109)	-99,759	-2,15,661	
Add : Notional Rent as per IND AS	1,13,323	2,53,168	
Less: Share of profit of Associates	-1,06,427	28,227	
Adjustment for Non Operating activities			
Add : Interest Paid	85,14,383	1,96,14,227	
Less : Interest income			
Cash Flow Before Working Capital changes:-	2,74,12,356	-6,69,07,771	
Decrease (Increase) in Inventories	11,43,563	3,98,20,084	
Decrease (Increase) in Trade receivables	-4,98,75,585	2,27,64,785	
Decrease (Increase) in other current assets	-8,78,897	2,56,48,425	
(Decrease) Increase in Short term borrowings	1,01,46,826	58,11,616	
(Decrease) Increase in Trade payables	1,68,27,854	-2,92,08,546	
(Decrease) Increase in Other Current liabilities	-15,05,779	-30,78,280	
(Decrease) Increase in Provisions	-2,71,833	77,09,911	
Cash Flow Before Tax and Extraordinary Items:-			
Income Taxes Paid			
Net Cash Flow From Operating Activities	29,98,506	25,60,225	
Cash Flow from Investing Activities:-			
Less : Purchase of Capital Assets	-1,16,52,821	-69,55,853	
Less : Purchase of Investments	-	-	
Add : Rental Receipts		14,315	
Add : Goodwill on Consolidation			
Add : Amount of Interest Received		1,20,000	
Less : Sale of Capital Assets		-2,00,124	
Decrease (Increase) in Loans and advances & Other assets	18,55,500		
Net Cash flow used in Investing Activities	-97,97,321	-70,21,662	
Cash Flow from Financing Activities:-			
Increase in Borrowings			
Interest Income Notional (As per Ind AS 109)	99,759	2,15,661	
Increase in Non Controlling interest		45,31,490	
Increase in Share capital			
Increase in Other Non current liabilities			
Interest expense	-85,14,383	-1,96,14,227	
Decrease in borrowings	1,18,74,203	1,20,94,882	
Net Cash Flow From Financing Activities	34,59,579	-27,72,194	
Net Increase/(Decrease) in Cash and Cash Equivalents:-			
(Opening Balance)	67,87,172	1,40,20,803	
Net Cash Flow during the year	-33,39,236	-72,33,632	
(Closing Balance)	34,47,936	67,87,172	

K. durga shankar

MANAGING DIRECTOR
DIN: 01295584



Notes:

1. The Unaudited Standalone and Consolidated financial results along with the Limited Review Report of the Statutory Auditors for the quarter and half year ended 30th September, 2021 are being forwarded to the Bombay stock exchange and is also available in the website of the Company (www.indrayani.com)
2. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors in the meeting held on 14th November,2021.
3. The Company operates in single business segment. Hence no segment wise reporting figures are published.
4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter
5. Previous period figures have been regrouped wherever necessary.



Place: Chennai

Date: 14.11.2021

K SAYEE SUNDAR

MANAGING DIRECTOR

DIN: 01295584



Limited Review Report on consolidated unaudited quarterly to date financial results of the company Pursuant to the regulation 33 of the SEBI(Listing Obligations and disclosure requirements) regulations, 2015

**TO THE BOARD OF DIRECTORS OF
Indrayani Biotech Limited**

We have reviewed the accompanying Statement of Consolidated Financial Results of Indrayani Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income / loss of its associates for the quarter ended **30th September, 2021** and for the period from **1st April 2021 to 30th September 2021** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended **30th September, 2020** and corresponding period from 1st April 2020 to 30th September 2020 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to audit/review.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial statements.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the unaudited results of the following entities:

- i. HSL Agri Solutions Private Limited – Subsidiary
- ii. IBL Healthcare Private Limited – Subsidiary
- iii. IBL Thiruvannamalai LLP _ Step down Subsidiary
- iv. HSL Prime Properties Private Limited - Associate

Based on our review conducted and procedures performed as stated in paragraph above and based on the consideration of the reports of the management referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.




We did not review the financial statement / financial information of **M/s. HSL Agri Solutions Private Limited** (subsidiary) included in the consolidated unaudited financial results, whose interim financial information for the Half year ended 30th September, 2021 reflects total revenues of **Rs.9.02 Lakhs**, total comprehensive profit / (loss) of **Rs (0.45) Lakhs** for the period ended on that date and in respect of **M/s. IBL Health Care Private Limited** (subsidiary) included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of **Rs. 33.28 Lakhs** total net profit / (Loss) after tax of **Rs.(11.15) Lakhs**, total comprehensive profit / (loss) of **Rs.(11.15) Lakhs** for the period ended on that date, as considered in the consolidated financial results and in respect of **M/s. IBL Thiruvannamalai LLP** (stepdown subsidiary) included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of **Rs.18.78 Lakhs**, total net profit / (Loss) after tax of **Rs.(10.38) Lakhs** for the period ended on that date, as considered in the consolidated financial results.

The consolidated financial results also include the Group's share of net profit / (Loss) of **Rs.1.06 Lakhs** and total comprehensive income of **Rs. 1.06 Lakhs** for the Period ended 30th September, 2021, in the consolidated financial results, in respect of **M/s. HSL Prime Properties Private Limited**, (Associate), whose financial statements / financial information have not been reviewed by us.

This financial information have been reviewed by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the Management and the procedures performed by us as stated in paragraph mentioned above.

For Venkatesh & Co
Chartered Accountants
F.R.No.004636S


CA Dasaraty V
Partner
M.No.026336



Place: Chennai
Date: 14/11/2021
UDIN: 21026336AAAAJR1769